ABLi Therapeutics Prepares for Phase 3 Trial of Disease-Modifying Drug Risvodetinib

Let’s face it—most treatments for Parkinson’s disease today do a decent job at managing the symptoms, but they don’t actually slow the disease itself. That’s why people are so excited about risvodetinib, a new drug being developed by ABLi Therapeutics, which could be the first to truly change the course of the disease. ABLi recently met with the U.S. Food and Drug Administration (FDA) to wrap up its successful Phase 2 trial and plan what’s next. Here's the exciting part: the FDA gave the green light to move ahead with a Phase 3 trial—and they agreed with some pretty bold ideas ABLi is bringing to the table. 🧪 What’s So Special About Risvodetinib? Risvodetinib (don’t worry about the name—we can call it “the new hope drug” for now) is taken once a day by mouth and targets a specific enzyme linked to the progression of Parkinson’s disease. This enzyme, called c-Abl kinase, plays a role in how damaging proteins build up in brain cells. Most Parkinson’s medications only treat symptoms—like tremors, stiffness, or slowness—but this drug aims to stop the disease in its tracks. Even more exciting, it might help clear out some of the harmful proteins (called alpha-synuclein) that are known to cause the damage in the first place. 📈 What Did the Phase 2 Trial Show? The drug was tested in people who hadn’t yet started taking levodopa (the gold-standard Parkinson’s medication). After just 12 weeks, participants on risvodetinib showed real improvements in their daily lives—things like dressing themselves, walking, and eating—measured using trusted scales like the MDS-UPDRS and Schwab & England Activities of Daily Living. And here's the kicker: it also showed signs of actually reducing the disease-causing proteins in the body. 🚀 What’s Next? ABLi is now getting ready for a big Phase 3 trial—the final step before they can apply for approval. The FDA liked their plan to use a very practical goal to measure success: how long people can go without needing levodopa. If the drug helps people delay starting levodopa, that’s a strong sign it's doing more than just masking symptoms—it may be slowing down the disease itself. 👀 Is It Safe? So far, yes. In the Phase 2 trial, nobody had serious side effects, and there were no problems with vision, which is sometimes a concern with similar drugs. The FDA is easing some of the strict vision testing requirements for the next phase, which is a good sign. 🔬 What About Tracking Progress? ABLi is also testing whether a small skin biopsy could help track how well the treatment is working, by measuring the level of those damaging proteins in the body. If that works, it could make monitoring Parkinson’s progression much easier in the future. 🧠 Why It Matters If risvodetinib lives up to its early promise, it could be the first true disease-modifying therapy for Parkinson’s—a treatment that doesn’t just manage symptoms but actually changes the trajectory of the disease. That’s why this next trial is so important—and why it’s worth keeping a close eye on.